In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Sage Therapeutics Inc. (focused on selective allosteric GABAA modulation) netted $561.3mm through the public offering of 3.8mm shares (including the overallotment) at $150. Sage will put the proceeds toward the US commercial launch of Zulresso (SAGE547; brexanolone) for postpartum depression, if approved (an NDA was filed in 2018 with an extended PDUFA date of March 19, 2019); ongoing development of and initial pre-commercial activities for SAGE217 in major depressive disorder (Phase III), bipolar depression (Phase II), and insomnia (Phase I); and advancement of Phase I candidates SAGE324 (essential tremor and epileptiform disorders) and SAGE718 (cognition-related disorders, including Huntington’s disease).
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?